Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F16IL2 + Paclitaxel in Advanced Solid Tumours
NCT01134250Phase 2Completed
- Sponsor
- Philogen
- Start
- Aug 2008
- Primary completion
- Apr 2014
- Modality
- Antibody Fragments, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of teleukin in solid tumor, breast cancer, melanoma and 1 more, sponsored by Philogen. Primary endpoints: Maximum Tolerated Dose and Recommended Dose at 28 days and Objective Response Rate at 8 weeks. Started Aug 2008; status: completed.
02
Drugs
teleukin
03
Conditions
solid tumorbreast cancermelanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01134250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01134250.